Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.45 |
| ▸ | DRD1 | P21728 | 8/20 | 0.45 |
| ▸ | DRD5 | P21918 | 8/20 | 0.45 |
| ▸ | DRD3 | P35462 | 7/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735928 | 0.79 | DRD2 (0.47) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL23735780 | 0.76 | MAOA (0.36) | DRD2DRD3MAOAMAOBSLC6A4 | |
| SCHEMBL16154960 | 0.75 | MAOA (0.53) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL20314836 | 0.75 | DRD2 (0.32) | DRD2DRD1DRD5DRD3BCL2 | |
| SCHEMBL23735746 | 0.74 | DRD2 (0.42) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL19304039 | 0.73 | GABRA1 (0.38) | DRD3MAOA | |
| SCHEMBL29310054 | 0.72 | CYP2D6 (0.40) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL24277006 | 0.70 | DRD2 (0.47) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL29310058 | 0.70 | MAOA (0.39) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL28587395 | 0.70 | GABRA1 (0.40) | DRD2DRD1DRD5DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | DRD2 1427/4885DRD1 1335/4885DRD5 2145/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | DRD2 4765/4885DRD1 4578/4885DRD5 4227/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DRD2 4767/4885DRD1 4565/4885DRD5 4282/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | DRD2 4844/4885DRD1 4737/4885DRD5 4659/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DRD2 4765/4885DRD1 4578/4885DRD5 4227/4885 |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DRD2 4765/4885DRD1 4578/4885DRD5 4227/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DRD2 4765/4885DRD1 4578/4885DRD5 4227/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DRD2 4732/4885DRD1 4444/4885DRD5 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.